ArticleCase reports in oncology
Remarkable Response to Iruplinalkib in an Elderly Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) typically affects younger patients. Management in elderly patients with significant comorbidities presents unique diagnostic and therapeutic challenges. Data regarding the efficacy and safety of iruplinalkib in elderly patients remain limited. Case Presentation: We report a 79-year-old male who presented with massive pleural effusion and multiple rib fractures. Initial diagnosis was established through pleural fluid cytology revealing adenocarcinoma. Following clinical stabilization, computed tomography-guided lung biopsy confirmed ALK-positive invasive adenocarcinoma. Treatment with iruplinalkib 180 mg once daily achieved a remarkable tumor response, with resolution of pleural effusion and significant reduction in tumor burden over 29 weeks. Treatment was well tolerated, with only mild gastrointestinal adverse events. Conclusion: This case demonstrates that iruplinalkib exhibits excellent efficacy and tolerability in elderly patients with ALK-positive NSCLC, even in those presenting with advanced disease and poor initial performance status. Age alone should not preclude consideration of targeted therapy when actionable driver mutations are identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.